← All trials
NCT05438316
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2022
- Primary completion
- Aug 2, 2022
- Completion date
- Nov 17, 2022
- First posted
- Jun 29, 2022
- Last posted
- Jun 29, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmtechnology LLCLead sponsor
- Ligand Research, LLCCollaborator
- Ligand Research, LLCOverall official - principal investigator
- Ligand Research, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.